# Performance and Long-term Safety of FlowOx2.0™ in Patients With Multiple Sclerosis - Impact on Spasticity and Pain

> **NCT05562453** · NA · UNKNOWN · sponsor: **Otivio AS** · enrollment: 56 (actual)

## Conditions studied

- Multiple Sclerosis
- Spasticity, Muscle
- Pain, Chronic

## Interventions

- **DEVICE:** FlowOx 2.0
- **DEVICE:** FlowOx2.0 (Sham)

## Key facts

- **NCT ID:** NCT05562453
- **Lead sponsor:** Otivio AS
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-04
- **Primary completion:** 2023-07-15
- **Final completion:** 2023-08-15
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2023-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05562453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05562453, "Performance and Long-term Safety of FlowOx2.0™ in Patients With Multiple Sclerosis - Impact on Spasticity and Pain". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05562453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*